Mirada Medical is a leading international brand in medical imaging. The company develops advanced technology applications that help healthcare professionals use medical images more effectively and efficiently to improve cancer care. The company specializes in simplifying technically complex image processing tasks, allowing clinicians to more confidently diagnose disease, assess response to treatment, and plan radiation therapy or surgical intervention.
Mirada’s advanced technology products are available throughout the world under its own brand, and on an OEM basis through a select number of the world’s leading healthcare companies. Mirada’s products are used in daily clinical practice at over 2,000 hospitals worldwide across diagnostic radiology, molecular imaging, radiation oncology, medical oncology, and tumour board.
Mirada R&D and Headquarters are based in Oxford, UK. The company has pioneered a number of significant technological innovations in the last two decades, from Fusion7D, the industry’s first clinical deformable image registration product back in 2002, to DLCExpertTM in 2018, the first FDA cleared deep learning product for contouring organs at risk in radiotherapy.
Mirada Medical and NCIMI
Mirada has partnered with NCIMI (National Consortium of Intelligent Medical Imaging) to investigate the role that AI and deep learning can play in diagnostic nuclear medicine. The company is building on established partnerships with Leeds Teaching Hospitals as well with the Alliance Medical Group and the NHS PET scanning program. Mirada software is already used to read more than half of the PET/CT scans in England & Wales.
This project aims to improve the efficiency and accuracy of cancer detection and diagnosis, leading to faster cancer treatment delivery, cost reductions for the NHS, and improved patient outcomes.
To learn more about Mirada Medical, please visit their website.
For more information, please contact email@example.com